Abstract: Transient Receptor Potential Vanilloid 1 (TRPV1) expressed in peripheral terminals is responsible for transducing thermal and chemical nociception. Role of TRPV1 expressed in the central terminals is not clear, however, its activation modulates synaptic transmission and contributes to central sensitization. In this study, we have determined the role of TRPV1 expressed in the peripheral and central terminals using resiniferatoxin (RTX), a potent TRPV1 agonist. A single intraplantar injection of RTX, within two days induced loss of capsaicin-induced nocifensive behavior and enhanced response latency to hot plate, which recovered over a period of two months. RTX treatment resulted in the ablation of peripheral TRPV1 expressing fibers in paw skin, which regenerated over the same time period. On the other hand, a single dose of intrathecal administration of RTX, within two days caused thermal hypoalgesia. RTX treatment ablated TRPV1 expressing central sensory nerve terminals. Intriguingly, in contrast to peripheral nerve terminal regeneration that occurred within two months, the central TRPV1 expressing nerve terminals did not regenerate even after five months. The present study demonstrates that TRPV1 in the peripheral and central terminals play a role in nociception and the peripheral terminals have the ability to regenerate, whereas the central terminals do not regenerate even after five months.
INTRODUCTION

Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca
2+ permeable non-specific cation channel. TRPV1 is predominately expressed in small diameter peptidergic dorsal root ganglion (DRG) and trigeminal ganglion neurons. TRPV1 is expressed in both peripheral and central terminals of the sensory neurons [1] [2] [3] [4] [5] . TRPV1 expressed at the peripheral terminals can be activated by a temperature (>43 ºC) and as a result transduces thermal pain sensitivity to the brain via the spinal cord [1, 6] . However, the role of TRPV1 expressed in the central terminals is far from clear. Activation of TRPV1 modulates synaptic transmission at the first sensory synapse between central terminals of DRG and dorsal horn neurons [1, 5, [7] [8] [9] [10] [11] . It is likely that peripheral injury-induced neuronal activity releases Calcitonin GeneRelated Peptide (CGRP) and Substance P (SP) from presynaptic nerve terminals and activation of glia influencing the synthesis and release of anandamide and proand anti-inflammatory mediators. Anandamide and inflammatory mediators act retrogradely to modulate synaptic transmission and TRPV1 expression and function, respectively [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Resiniferatoxin (RTX) is an ultrapotent TRPV1 agonist, which activates TRPV1 in an irreversible manner. As a result, TRPV1 nerve terminals are ablated by persistent increase in Ca 2+ influx [5, [23] [24] [25] . Therefore, it would be useful to use RTX to target TRPV1 to *Address correspondence to these authors at the Department of Clinical Medicine, Michigan State University, Lansing, MI 48824, USA; Tel: 217-545-2179; Fax: 217-545-0145; E-mails: lpremkumar@siumed.edu and sqyu@msu.edu treat conditions such as peripherally mediated inflammatory pain including shingles, urinary bladder hyperreflexia, deiabetic peripheral neuropathy, arthritis etc. On the other hand, TRPV1 expressed at the central nerve terminals can be targeted to treat debilitating pain conditions such as pain associated with cancer. To test the effectiveness of intrathecal administration of RTX in treating cancer pain, a clinical trial has been initiated by National Institute of Dental and Craniofacial Research (NCT00804154). Usefulness of RTX has been shown in several modalities of pain [24, [26] [27] [28] [29] [30] [31] . Karai et al. [26] reported that intraplantar administration of RTX produced thermal antinociception without affecting basal pain sensitivity. Neubert et al., [27] reported that regeneration of peripheral nerve endings was observed after RTX treatment. However more direct morphological and functional studies need to be conducted.
In order to study the role of TRPV1 expressed in peripheral and central terminals, we targeted TRPV1 by its antagonists or by RTX, which caused TRPV1 expressing nerve terminal ablation. We determined the nocifensive behavior to capsaicin, thermal sensitivity and the ability of the peripheral and central terminals to regenerate following RTX treatment.
EXPERIMENTAL PROCEDURES
Animals
TRPV1 knockout mice (B6.129S4-Trpv1tm1Jul/J) were purchased from The Jackson Laboratory and maintained as homozygous mutants [32] . Rats (SD, male, 250-300 g) and wild-type mice (C57Bl6/J, background strain of TRPV1 knock-out, male, 25-30 g) were purchased from Harlan (Indianapolis, IN, USA). All animals were housed on a 12-hour light/dark cycle with free access to food and water. Mice and rats were accustomed to the testing environment for 5 days prior to the first testing day to decrease the effect of stress. All experiments reported in this study were conducted in accordance with the protocols approved by the Laboratory Animal Care and Use Committee of Southern Illinois University School of Medicine.
Ablation of TRPV1 Expressing Peripheral and Central Terminals
20 μl of 1, 3 or 10 μM of RTX was injected intraplantarly into the left hind paw of mice to ablate the TRPV1 expressing peripheral terminals. 10 μl of 100 μM of RTX were injected intrathecally in rats to ablate the TRPV1 expressing central terminals.
Nocifensive Behavior Test
Capsaicin-evoked nocifensive behavior in mice was defined as licks/shakes [33] . The number of times the mouse licked/shook its left hind paw was counted over 3 min immediately after intraplantar administration of capsaicin (100 μM, 20 μl) or saline into the left hind paw.
Hot Plate Test
The hot plate test was used to measure response latencies to thermal stimulation. The mouse was placed on the heated surface of the hot plate apparatus (Columbus Instruments, Columbus, Ohio), which was maintained at 49.5±0.5 ºC. The pain response was evaluated by recording the latency (s) for the mouse to shake or lick the hind paw or to jump from the hot plate (whichever occurred first). A cut-off time of 40 s was set to avoid injury to the paws. All mice were accustomed to the pain test conditions for 5 days before the experiments. The hot plate test was conducted before and repeated at 2, 4, 7, 14, 21, 28, 35, 42, 49, 56 , 63 days after intraplantar injection of RTX or saline.
Intrathecal Catheter Implantation and Intrathecal Injection
Surgery: Intrathecal catheters were implanted in rats according to Yaksh and Rudy 1976, [34] with some modifications. Briefly, rats were anesthetized with ketamine/xylazine (85/5 mg/kg, i.p.). When they no longer responded to the tail pinch test, the nape area was shaved. The skin was swabbed with betadine followed by 70 % alcohol. A small incision was made in the skin and the muscles were separated to expose the atlanto-occipital membrane (the dura mater between the atlas and os occipitale). A small incision was made in the membrane to allow a polyethylene-10 catheter filled with 0.9 % sterile saline to be inserted into the subarachnoid space. The catheter was threaded through the space as far as the lumbar enlargement (7.5 cm from the atlanto-occipital membrane to the lumbar enlargement). The catheter was then sutured in place with the muscles and the incision closed. About 5 cm of catheter was left externally to act as an external port for injections. The external port was sealed with Parafilm film to ensure that the cerebrospinal fluid will not flow out via the catheter. Rats were allowed to recover for 7 days after surgery. To prevent infection, 10 mg/kg of kanamycin was injected subcutaneously everyday for 5 days during recovery. Intrathecal administration of drugs: Drugs (10 μl) were administrated into the subarachnoid space via the catheter, which was flushed with 10 μl of saline to ensure complete release of the drugs in the subarachnoid space.
Radiant Heat Test
To assess thermal nociceptive responses, a radiant heat instrument (Ugo Basile, Cat. No 7370) was employed [35] . The thermal nociceptive stimulus (radiant heat), originated from a focused projection bulb, was delivered to the plantar surface of rat hind paw. A timer was automatically activated with the light source, and paw withdrawal latency (PWL) was defined as the time required for the paw to show an abrupt withdrawal. Intensity of the heat source was adjusted to yield PWL ranging from 7 to 10 s for normal rats, and a cutoff time of 20 s was imposed to avoid tissue damage.
Immunohistochemistry
Mice or rats were anesthetized by ketamine/xylazine (85/5 mg/kg, ip). Freshly made fixative (4 % paraformaldehyde) was perfused transcardially. L5 DRGs, the ventral skin of hind paw, and lumbar spinal cord were removed and kept in the same fixative for 3 hours, then incubated with 15 % sucrose and 30 % sucrose for 12 hours, respectively. Samples were quickly frozen with liquid nitrogen. DRG, skin and spinal cord were cut into sections with a thickness of 10, 20 and 20 μm, respectively. After being perforated with PBS containing 0.1 % Triton X-100 for 20 minutes and blocked with 10 % donkey serum for 30 minutes, the sections of mouse samples were incubated with polyclonal rabbit anti-TRPV1 antibody (Calbiochem, PC420, 1:50) for one hour at room temperature, the sections of rat samples were incubated with polyclonal rabbit anti-TRPV1 antibody (Affinity BioReagents, PA1-747, 1:500) and monoclonal mouse anti-NeuN antibody (Chemicon, MAB377, 1:100) for 1 hour at room temperature, then the sections were incubated with Rhodamine RedTM-X donkey anti-rabbit IgG (Jackson, 711-295-152, 1: 100) and FITC donkey anti-mouse IgG (Jackson, 715-095-151, 1: 100) for 1 hour at room temperature, then spread on slides, mounted with mounting medium (Biomeda Gel/Mount) and covered by cover slips. Pictures were taken by using confocal microscope (Olympus Fluoview).
The quantification of staining was as follows. The DRG was horizontally cut into sections. Only the full size sections (which include three intact parts, the two soma-concentrating lateral parts and the fiber-concentrating central part) were taken into account. The paw skin was longitudinally cut into sections. Only the TRPV1 staining in the small region between the second foot pad and the fifth foot pad was taken into account. The spinal cord was transversely cut into sections. Only the TRPV1 staining in the superficial layers of the dorsal horn was taken into account. Ten sections were selected randomly from these full size sections. The numbers of the stained TRPV1 neurons he total gray values were measured by ImageJ ((http://rsb.info.nih.gov/ij/). Reagents RTX (R8756, Sigma-Aldrich) was dissolved in 95 % ethanol and used as a stock solution. 1, 3 and 10 μM of working concentrations of RTX were made by diluting the stock RTX in sterilized 0.9 % NaCl. Capsaicin (M2028, Sigma-Aldrich) was dissolved in 95 % ethanol and used as a stock solution. 100 μM of working concentration of capsaicin was made by diluting the stock capsaicin in sterilized 0.9 % NaCl. Capsazepine (C191, Sigma-Aldrich) was dissolved in 95 % ethanol and used as a stock solution. 0.3, 1 and 3 mM of working concentrations of capsazepine were made by diluting the stock capsaicin in sterilized 0.9 % NaCl.
Statistical Analysis
All data are reported as mean ± SE, differences between groups were analyzed statistically by the Student t-test with the level of significance set at * P<0.05.
RESULTS
Intraplantar Administration of RTX Abolished Capsaicin-induced Nocifensive Behavior in Mice
RTX is a potent TRPV1 agonist that can activate the receptor irreversibly by binding with high affinity. In order to study the effect of RTX in the peripheral nerve terminals, a series of concentrations of RTX (1, 3 and 10 μM, 20 μl) was injected into the plantar surface of mice (n=4) left hind paw. Since capsaicin is a TRPV1 agonist that can induce nocifensive behavior when injected into the plantar region, we determined capsaicin (100 μM, 20 μl)-induced nocifensive behavior in the RTX-treated mice every other day during the first week and once a week thereafter. A dose-dependent loss of capsaicin-induced nocifensive behavior was observed two days after RTX administration as compared to the control group. Especially higher concentration of RTX (10 μM) caused complete loss of capsaicin-induced nocifensive behavior. Capsaicin-induced loss of nocifensive behavior gradually recovered to the basal level over a period of sixty three days following treatment with RTX (Fig. 1) .
Intraplantar Injection of RTX Enhanced the Response Latency to Hot Plate in Mice
Once it was determined that 10 μM of RTX was an effective concentration, we next examined the changes in thermal sensation in mice (n=13-25) treated with 10 μM intraplantar RTX. A strong thermal anti-nociception was observed in the RTX-treated mice indicated by the enhanced response latency to the hot plate test, which remarkably increased to the cut-off time (40 s) within two days following RTX treatment. The mice were subjected to hot plate test twice a week for the first three weeks and once a week thereafter. The response latency decreased gradually over a period of 2 months. The control mice injected with saline showed no change in response latency, when subjected to hot plate test. We also used TRPV1 knockout mice that showed a moderate increase in response latency as compared to RTX-treated animals (Fig. 2) . In order to determine whether the loss and recovery of capsaicin-induced nocifensive behavior and the thermal antinociception were due to ablation and regeneration of TRPV1 expressing nerve fibers, we used immunohistochemical methods and stained for TRPV1 expressing fibers. The paw skin of the RTX-and salinetreated mice were collected at different days following treatment. There was no TRPV1-staining observed in mouse paw skin, within two days of intraplantar administation of RTX (10 μM, 20 μl). However, the nerve fibers regenerated gradually over a period of time and a substantial regeneration of TRPV1-expressing fibers was observed in mouse paw skin over the period of two months (Fig. 3) . We also examined the change in TRPV1 expressing cell bodies by immunostaining the L5 DRG. There was neither a change in the number of neuronal cell bodies stained nor in the intensity of staining (Fig. 4) .
Intrathecal Administration of TRPV1 Antagonist Capsazepine Induced Anti-nociception in Rats
Then, we examined the role of TRPV1 expressed in central terminals by administering capsazepine (0.3, 1 and 3 mM, 10 μl) into the subarachnoid space of rats (n=8). A short-term transient dose-dependent thermal hypoalgesia was observed after capsazepine administration as compared to the control group (Fig. 5) . This suggests that block of TRPV1 expressed in the central terminals plays a role in thermal nociception. The transient nature of response might be due to diffusion of the antagonist in the cerebrospinal fluid.
Intrathecal Administration of RTX Enhanced the PWL to Radiant Heat in Rats
Since peripheral TRPV1 expressing nerve terminal ablation by RTX resulted in thermal hypoalgesia, which recovered over a period of 2 months, we wanted to determine the role of TRPV1 expressed in the central nerve terminals by intrathecal administration of RTX (100 μM, 10 μl). We chose rats for these studies because of the ease with which intrathecal administration can be performed. However, We will have to take into account effects associated with species difference. PWL was determined using a radiant heat source and testing was carried out every four days over a period of three weeks. There was a significant increase in PWL following administation of a single dose of RTX (Fig. 6) . Most interesting observation is that unlike following intraplantar RTX administration (Figs. 1 and 2) , the PWL did not decrease or recover over time (n=5-6). We have attributed the recovery of thermal sensitivity following peripheral RTX administration to regeneration of the nerve terminals.
In order to exclude the possibility of nonspecific effects, we conducted the experiments by intrathecal administration of capsazepine in RTX-treated rats (10 μM, 10 μl at 7 days after RTX) (n=8), in which the TRPV1 expressing central nerve terminals were ablated. There was no change in thermal pain sensitivity suggesting that the common target for capsazepine and RTX is TRPV1 (Fig. 7) .
Ablation and Regeneration of TRPV1 Expressing Central Sensory Nerve Terminals by RTX
In order to further examine the effects of intrathecal RTX administration, we used immunohistochemistry. The spinal cord tissue was collected after seven days following intrathecal administration of RTX (100 μM, 10 μl) and stained for TRPV1. There was no TRPV1 labeling observed in dorsal horn following RTX treatment, however labeling of dorsal horn neuronal cell bodies with NeuN, a neuronal marker was unaffected.
Since there was no recovery from enhanced PWL, we determined the regeneration of central terminals over a period by staining the spinal cord tissue for TRPV1 at different time points. Intriguingly, even after 5 months following RTX treatment, there was no TRPV1 staining observed in the dorsal horn suggesting that TRPV1 expressing central terminals did not regenerate after RTX administration (Fig. 8) . Fig. (7) . Effects of intrathecal administration of capsazepine on PWL to radiant heat in central TRPV1-ablated rats by RTX. Time = 0 min: intrathecal injection of 10 μl of 3 mM of capsazepine, or 10 μl of 0.9 % saline as the control group. Data are presented as mean ± SE, paw withdrawal latency to radiant heat (s). Horizontal axis indicates time (min) after the capsazepine. The statistical difference at time points between groups was evaluated by Student's t-test. *P<0.05 compared with the control group.
It could be argued that the DRG neuronal cell bodies were ablated by intrathecal administration of RTX, hence the inability of the central terminals to regenerate. Therefore, we determined the number of TRPV1 expressing neurons and their intensity of staining in L5 DRG in RTX-treated animals. There was no difference in the number of TRPV1 expressing neurons or in their intensity of staining (Fig. 9) . Based on this observation, it is tempting to suggest that central TRPV1 expressing sensory nerve terminals do not have the ability to regenerate as compared to peripheral sensory nerve terminals.
DISCUSSION
Ablation of peripheral sensory nerve terminals by a single intraplantar injection of RTX resulted in the loss of TRPV1 staining in plantar skin, which correlated with the loss of capsaicin-induced nocifensive behavior and thermal sensitivity. Over a period of two months, a gradual recovery of nocifensive behavior, thermal sensitivity and TRPV1 staining were observed, suggesting regeneration of ablated nerve terminals.
Ablation of central sensory nerve terminals by a single intrathecal administration of RTX resulted in the loss of TRPV1 staining in the laminae I and II of the spinal cord and enhanced PWL to radiant heat. However, unlike the peripheral nerve terminals, neither the PWL nor the TRPV1 staining recovered, suggesting the inability of the central terminals to regenerate.
As alluded to earlier, it could be argued that the DRG neuronal loss by the intrathecal administration of RTX could prevent the regeneration, as it has been shown that intrathecal delivery of antisense oligodeoxynucleotide can be retrogradely transported in sufficient concentrations that can induce DRG neuronal cell death [36] . In order to test this possibility, we stained the L5 DRG for TRPV1. Following intrathecal administration of RTX, the number of cell bodies stained for TRPV1 remained the same and the intensity of staining was also unaffected as compared to control saline administered animals. TRPV1 is a polymodal receptor involved in the transduction of chemical and thermal sensitivities. Interestingly, the antinociceptive effect of RTX-treated mice was greater than TRPV1 knockout mice, which may suggest other nociceptive receptors such as TRPV2, TRPV3 or TRPM8 may play a role in thermal nociception. Studies have shown that TRPV1 and TRPV2, TRPV3, NK1, SP and CGRP are co-localized in the same DRG neuron [6, [37] [38] [39] [40] . Ablation of TRPV1-expressing nerve terminals will also eliminate other nociceptive ion channels and metabotropic receptors that modulate TRPV1 function. It should also be taken into consideration, the role of TRPV1 expressed in the gabargic interneurons in the spinal cord [41] .
There is a dense distribution of TRPV1 in dorsal horn of spinal cord of rats and mice [1, 6, 5] , which suggests that there may be functions associated with central TRPV1, although yet to be demonstrated. In this study, we have demonstrated that thermal anti-nociception could be induced by blocking TRPV1 by its antagonist, capsazepine. This was confirmed by the observation that thermal hypoalgesia occurred following intrathecal administration of ultra-potent TRPV1 agonist, RTX. Taken together these observations demonstrate that TRPV1 in the dorsal horn of rat spinal cord plays a role in thermal nociception. Besides, intrathecal administration of RTX ablated only TRPV1 expressing central terminals rendering a novel strategy to selectively study the role of TRPV1 in the central terminals of the sensory neurons.
Administration of intrathecal RTX resulted in the loss of TRPV1 staining, which is interpreted as ablation of TRPV1 expressing nerve terminals. The loss of thermal sensation and TRPV1 staining in the spinal dorsal horn following intrathecal administration of RTX did not recover over a period of five months, suggesting the inability of the central nerve terminals to regenerate following RTX treatment. One of the criticisms for the strategy of intrathecal administration of RTX is that, although the pain relief is effective, the process of regeneration could make the pain condition worse because of indiscriminate, unorganized and excessive nerve fiber regeneration. However, it was surprising to learn that the central terminal did not regenerate following RTXinduced ablation. Therefore, the danger of excessive regeneration can be prevented; nevertheless, ablating central nerve terminals is not a preferred outcome that might have long-term consequences. It is commendable that a clinical trial has begun specifically to treat terminal debilitating cancer pain conditions (National Institute of Dental and Craniofacial Research, NCT00804154).
Injury-induced neuronal activity releases CGRP and SP from the central nerve endings of the sensory neurons, which is partly mediated by TRPV1. Once released, these neuropeptides bind to their receptors on neurons and glia and trigger downstream signaling events leading to central sensitization [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Neuronal activity increases endovanilloid levels during chronic pain conditions, which are synthesized and released on demand [42] [43] [44] [45] [46] . Studies have shown that blocking neuropeptide release alleviates inflammatory [47] [48] [49] and neuropathic pain [50] . Drugs that inhibit activation of glia have been shown to alleviate chronic pain [51] . Similarly, gene therapy that increases the levels of anti-inflammatory mediators has been shown to alleviate chronic pain [52] [53] [54] . TRPV1 expressed in the central terminals could be a target for modulation by these processes.
CONCLUSION
In conclusion, our studies show that RTX administration can ablate peripheral TRPV1 expressing nerve fibers temporally without affecting their regeneration capability. The accompanying effects of loss of nocifensive behavior and thermal hypoalgesia recovered overtime shed insight into potential therapeutic strategies that can be developed to treat certain modalities of pain involving peripheral nerves such as diabetic peripheral neuropathy, shingles, urinary bladder hyperreflexia and arthritis. On the other hand, intrathecal administation of TRPV1 agonists can provide long-lasting pain relief by ablating TRPV1 expressing central sensory nerve terminals in the dorsal horn. Although RTX is in clinical trials, nerve terminal ablation is not a preferred outcome. However, further research can be undertaken to cause partial ablation by manipulating concentrations of RTX or using less potent TRPV1 agonists.
